In this article, we are going to take a look at where Guardant Health (NASDAQ:GH) stands against the other stocks. Stock gains always get people talking, and 2025 is no exception. Markets have ...

BTIG raised the firm’s price target on Guardant Health (GH) to $55 from $50 and keeps a Buy rating on the shares. The firm reiterated Guardant as a Top Pick, noting that the shares are up ...

In this article, we are going to take a look at where Guardant Health, Inc. (NASDAQ:GH) stands against the other stocks. Wall Street’s main indices kicked off the trading week soaring on Tuesday ...

Barclays initiated coverage of Guardant Health (GH) with an Overweight rating and $60 price target The firm started the liquid biopsy space with Overweight ratings on three names. The technology ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology ...

Medicare now covers Guardant Reveal for monitoring colorectal cancer recurrence after curative therapy. Analyst sees expanded coverage boosting revenue and improving gross margins by year-end.

Guardant Health (GH) shares rallied 6.3% in the last trading session to close at $35.88. This move can be attributable to notable volume with a higher number of shares being traded than in a ...